Xenetic Biosciences, Inc. current report, 01 March 2019

Abrir documento

Xenetic Biosciences, Inc. Form 8-K Summary

Business Context and Reporting Period

Date of Report: March 1, 2019 (Event Date: March 1, 2019; Announcement Date: March 4, 2019)
Company: Xenetic Biosciences, Inc.
Context: The Company entered into definitive agreements to acquire the "XCART" platform, a novel Chimeric Antigen Receptor T Cell (CAR T) technology designed for personalized treatment of B-cell Non-Hodgkin lymphomas. The technology was developed by The Scripps Research Institute in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBCH).

Key Financial Metrics and Transaction Terms

This filing details a material definitive agreement involving equity issuance rather than cash flow or revenue metrics. The filing text does not provide current revenue, profit, cash flow, or debt figures.

  • Consideration for Hesperix Acquisition: Issuance of 4,875,000 shares of Xenetic common stock to sellers of Hesperix SA.
  • Consideration for OPKO/IP Assignment: Issuance of 1,968,750 shares to OPKO Pharmaceuticals, LLC and 656,250 shares to The Scripps Research Institute.
  • Total Equity Issuance: Approximately 7.5 million shares of common stock to be issued upon closing.
  • Valuation Method: Share issuance is fixed regardless of the trading price of Xenetic common stock at the time of closing.
  • Royalties: Hesperix agreed to pay IBCH and Pharmsynthez a royalty rate in the low single-digit range on net sales. The Institute will receive a similar royalty rate from the Company.

Material Changes and Transaction Structure

The Company is executing a multi-party transaction to consolidate rights to the XCART technology:

  • Share Purchase Agreement: Acquisition of 100% of Hesperix SA shares from various sellers.
  • Hesperix Assignment Agreement: Assignment of patent rights and know-how from IBCH and Pharmsynthez to Hesperix.
  • OPKO Assignment Agreement: Acquisition of OPKO's rights under an existing IP License Agreement with The Scripps Research Institute.
  • Related Party Transactions:
    • Pharmsynthez (controlling stockholder, ~57.1% ownership) is a party to the assignment agreements and voting agreements.
    • OPKO Health (owns ~4.3% of Xenetic) is the parent of OPKO Pharmaceuticals, LLC.

Guidance, Outlook, Risks, and Contingencies

Outlook and Timeline:

  • The transaction is expected to close in the first half of 2019, subject to closing conditions.
  • Closing is contingent upon the Company obtaining adequate financing for future working capital obligations.
  • Closing requires stockholder approval of the Share Purchase Agreement and issuance of Transaction Shares.
  • Termination date: If closing conditions are not fulfilled by July 1, 2019, the agreements may be terminated.
Risks and Contingencies:
  • Financing Risk: The transaction is conditional on the Company securing adequate financing for post-closing working capital.
  • Regulatory and Approval Risk: Failure to obtain necessary stockholder approvals or regulatory clearances.
  • Development Risk: Uncertainty regarding the clinical development of the XCART platform and its ability to demonstrate a superior safety profile compared to existing therapies.
  • Lock-Up Agreements: Sellers, OPKO, and the Institute have agreed to 180-day lock-up periods on the shares received.
Management Commentary:

Management believes the XCART platform has the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient-specific CAR T cells, potentially limiting off-tumor toxicities such as B-cell aplasia.

Key Facts for Investor Verification

  • Financing Status: Verify if the Company has secured the "adequate financing" required as a closing condition.
  • Stockholder Approval: Monitor the upcoming stockholder meeting for approval of the issuance of ~7.5 million new shares.
  • Dilution Impact: Assess the dilution effect of the fixed share issuance regardless of market price.
  • Related Party Conflicts: Review the specific terms involving Pharmsynthez (controlling shareholder) and OPKO Health (significant shareholder) in the assignment and voting agreements.
  • Clinical Data: Review the attached corporate presentation (Exhibit 99.2) for details on the preclinical proof of mechanism and the status of the XBIO-101 Phase 2 trial.